… in a panel discussion focused on emerging treatment options in cystic fibrosis during the JMP Securities Life … cystic fibrosis, Leber’s congenital amaurosis Type 10 and dystrophic epidermolysis bullosa. Based on our unique proprietary RNA repair platform technologies we are growing …
… cystic fibrosis, Leber's congenital amaurosis 10 and dystrophic epidermolysis bullosa, today announced a … Vienna, Austria. The presentation titled “IPRP UPLC Method Optimization for the Separation of Short- and Longmer … and dystrophic epidermolysis bullosa. Based on our unique proprietary RNA repair platform technologies we are growing …
LEIDEN, Netherlands, Sept. 18, 2014 (GLOBE NEWSWIRE) -- ProQR Therapeutics today announced the pricing of its initial public offering of 7,500,000 ordinary shares at an initial public offering price of $13.00 per ordinary share.
… NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through … offering, ProQR expects to grant the underwriters a 30-day option to purchase additional ordinary shares, on the same … to fund its clinical trials, ongoing research and development activities and for working capital and other …
… Chief Scientific Officer Proven leader with deep worldwide ophthalmology experience, including multiple approvals … MD, who is departing ProQR. Dr. Shams brings to ProQR deep ophthalmology, scientific and research management experience, … as Senior Corporate Officer, Head of Global Research and Development and Chief Scientific Officer at Santen, a global …
… lives through transformative RNA therapies based on its proprietary Axiomer ® RNA editing technology platform, today … led to approx. 50% editing in liver of mice. New optimizations are being evaluated (not disclosed in the … prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing …
